Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Distler

Showing results (371-380 of 621) with videos related to

Pageof 63
Sort By:
Arthritis Research & Therapy|October 29, 2020
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR databaseYannick Allanore, Sylvie Bozzi, Augustin Terlinden, et al.
RMD Open|February 3, 2022
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohortAdrian Ciurea, Seraphina Kissling, Kristina Bürki, et al.
Communications Biology|February 24, 2023
Author Correction: The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditionsMara Stellato, Matthias Dewenter, Michal Rudnik, et al.
Communications Biology|February 9, 2023
The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditionsMara Stellato, Matthias Dewenter, Michal Rudnik, et al.
Swiss Medical Weekly|April 5, 2024
Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohortKevin Windirsch, Suzana Jordan, Mike Oliver Becker, et al.
Chest|October 16, 2022
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and ResearchAnna-Maria Hoffmann-Vold, Cathrine Brunborg, Paolo Airò, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
RMD Open|November 10, 2023
Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomesTea Gegenava, Federico Fortuni, Nina Marijn van Leeuwen, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertensionPanagiota Xanthouli, Suzana Jordan, Nicklas Milde, et al.
British Journal of Pharmacology|July 7, 2020
Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouseLaetitia Ledein, Bertrand Léger, Clara Dees, et al.
Pageof 63

Showing results (371-380 of 621) with videos related to

Sort By:
Pageof 63
Arthritis Research & Therapy|October 29, 2020
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR databaseYannick Allanore, Sylvie Bozzi, Augustin Terlinden, et al.
RMD Open|February 3, 2022
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohortAdrian Ciurea, Seraphina Kissling, Kristina Bürki, et al.
Communications Biology|February 24, 2023
Author Correction: The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditionsMara Stellato, Matthias Dewenter, Michal Rudnik, et al.
Communications Biology|February 9, 2023
The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditionsMara Stellato, Matthias Dewenter, Michal Rudnik, et al.
Swiss Medical Weekly|April 5, 2024
Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohortKevin Windirsch, Suzana Jordan, Mike Oliver Becker, et al.
Chest|October 16, 2022
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and ResearchAnna-Maria Hoffmann-Vold, Cathrine Brunborg, Paolo Airò, et al.
Clinical and Experimental Rheumatology|July 29, 2021
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationaleRobert Spiera, Dinesh Khanna, Masataka Kuwana, et al.
RMD Open|November 10, 2023
Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomesTea Gegenava, Federico Fortuni, Nina Marijn van Leeuwen, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertensionPanagiota Xanthouli, Suzana Jordan, Nicklas Milde, et al.
British Journal of Pharmacology|July 7, 2020
Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouseLaetitia Ledein, Bertrand Léger, Clara Dees, et al.
Pageof 63